Medical - Instruments & Supplies
Compare Stocks
5 / 10Stock Comparison
STVN vs APOG vs BCPC vs AWI vs INGR
Revenue, margins, valuation, and 5-year total return — side by side.
Construction
Chemicals - Specialty
Construction
Packaged Foods
STVN vs APOG vs BCPC vs AWI vs INGR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Construction | Chemicals - Specialty | Construction | Packaged Foods |
| Market Cap | $4.92B | $787M | $5.11B | $7.05B | $6.77B |
| Revenue (TTM) | $1.18B | $1.40B | $1.06B | $1.65B | $7.22B |
| Net Income (TTM) | $139M | $54M | $158M | $306M | $729M |
| Gross Margin | 29.0% | 22.7% | 36.3% | 40.3% | 25.3% |
| Operating Margin | 16.5% | 6.7% | 21.0% | 27.5% | 14.1% |
| Forward P/E | 29.3x | 10.6x | 30.9x | 19.9x | 9.6x |
| Total Debt | $471M | $286M | $192M | $532M | $1.79B |
| Cash & Equiv. | $131M | $40M | $75M | $113M | $1.03B |
STVN vs APOG vs BCPC vs AWI vs INGR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Stevanato Group S.p… (STVN) | 100 | 89.3 | -10.7% |
| Apogee Enterprises,… (APOG) | 100 | 92.2 | -7.8% |
| Balchem Corporation (BCPC) | 100 | 118.2 | +18.2% |
| Armstrong World Ind… (AWI) | 100 | 152.6 | +52.6% |
| Ingredion Incorpora… (INGR) | 100 | 122.3 | +22.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: STVN vs APOG vs BCPC vs AWI vs INGR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
STVN lags the leaders in this set but could rank higher in a more targeted comparison.
APOG ranks third and is worth considering specifically for valuation efficiency.
- PEG 0.32 vs STVN's 2.48
- Lower P/E (10.6x vs 19.9x)
Among these 5 stocks, BCPC doesn't own a clear edge in any measured category.
AWI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 12.1%, EPS growth 17.6%, 3Y rev CAGR 9.5%
- 330.4% 10Y total return vs BCPC's 160.5%
- 12.1% revenue growth vs INGR's -2.8%
- 18.6% margin vs APOG's 3.9%
INGR is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 3 yrs, beta 0.25, yield 3.0%
- Lower volatility, beta 0.25, Low D/E 41.0%, current ratio 2.66x
- Beta 0.25, yield 3.0%, current ratio 2.66x
- Beta 0.25 vs STVN's 1.45
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.1% revenue growth vs INGR's -2.8% | |
| Value | Lower P/E (10.6x vs 19.9x) | |
| Quality / Margins | 18.6% margin vs APOG's 3.9% | |
| Stability / Safety | Beta 0.25 vs STVN's 1.45 | |
| Dividends | 3.0% yield, 3-year raise streak, vs APOG's 2.8% | |
| Momentum (1Y) | +11.5% vs INGR's -18.4% | |
| Efficiency (ROA) | 16.0% ROA vs APOG's 4.8%, ROIC 24.9% vs 8.1% |
STVN vs APOG vs BCPC vs AWI vs INGR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
STVN vs APOG vs BCPC vs AWI vs INGR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AWI leads in 3 of 6 categories
APOG leads 1 • STVN leads 0 • BCPC leads 0 • INGR leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AWI leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
INGR is the larger business by revenue, generating $7.2B annually — 6.8x BCPC's $1.1B. AWI is the more profitable business, keeping 18.6% of every revenue dollar as net income compared to APOG's 3.9%. On growth, BCPC holds the edge at +8.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.2B | $1.4B | $1.1B | $1.6B | $7.2B |
| EBITDAEarnings before interest/tax | $283M | $57M | $267M | $603M | $1.2B |
| Net IncomeAfter-tax profit | $139M | $54M | $158M | $306M | $729M |
| Free Cash FlowCash after capex | $16M | $95M | $182M | $247M | $809M |
| Gross MarginGross profit ÷ Revenue | +29.0% | +22.7% | +36.3% | +40.3% | +25.3% |
| Operating MarginEBIT ÷ Revenue | +16.5% | +6.7% | +21.0% | +27.5% | +14.1% |
| Net MarginNet income ÷ Revenue | +11.8% | +3.9% | +15.0% | +18.6% | +10.1% |
| FCF MarginFCF ÷ Revenue | +1.4% | +6.8% | +17.2% | +15.0% | +11.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.8% | +1.6% | +8.1% | +7.1% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.6% | +6.1% | +10.6% | -1.9% | +79.0% |
Valuation Metrics
APOG leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 9.6x trailing earnings, INGR trades at a 71% valuation discount to BCPC's 33.6x P/E. Adjusting for growth (PEG ratio), APOG offers better value at 0.43x vs STVN's 2.64x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.9B | $787M | $5.1B | $7.0B | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $5.3B | $1.0B | $5.2B | $7.5B | $7.5B |
| Trailing P/EPrice ÷ TTM EPS | 31.31x | 14.52x | 33.58x | 23.32x | 9.61x |
| Forward P/EPrice ÷ next-FY EPS est. | 29.32x | 10.64x | 30.87x | 19.87x | 9.56x |
| PEG RatioP/E ÷ EPS growth rate | 2.64x | 0.43x | 2.62x | — | 0.57x |
| EV / EBITDAEnterprise value multiple | 16.89x | 21.95x | 19.83x | 17.23x | 5.98x |
| Price / SalesMarket cap ÷ Revenue | 3.68x | 0.56x | 4.92x | 4.35x | 0.94x |
| Price / BookPrice ÷ Book value/share | 2.82x | 1.53x | 4.14x | 7.99x | 1.60x |
| Price / FCFMarket cap ÷ FCF | 195.36x | 8.27x | 29.51x | 28.63x | 13.25x |
Profitability & Efficiency
AWI leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AWI delivers a 34.8% return on equity — every $100 of shareholder capital generates $35 in annual profit, vs $10 for STVN. BCPC carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to AWI's 0.59x. On the Piotroski fundamental quality scale (0–9), BCPC scores 9/9 vs STVN's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.7% | +10.8% | +12.4% | +34.8% | +17.1% |
| ROA (TTM)Return on assets | +5.8% | +4.8% | +9.4% | +16.0% | +9.4% |
| ROICReturn on invested capital | +7.7% | +8.1% | +12.2% | +24.9% | +15.5% |
| ROCEReturn on capital employed | +9.5% | +9.7% | +14.8% | +26.5% | +16.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 9 | 9 | 8 |
| Debt / EquityFinancial leverage | 0.32x | 0.56x | 0.15x | 0.59x | 0.41x |
| Net DebtTotal debt minus cash | $340M | $247M | $117M | $419M | $760M |
| Cash & Equiv.Liquid assets | $131M | $40M | $75M | $113M | $1.0B |
| Total DebtShort + long-term debt | $471M | $286M | $192M | $532M | $1.8B |
| Interest CoverageEBIT ÷ Interest expense | 20.54x | 5.97x | 15.23x | 13.31x | 27.32x |
Total Returns (Dividends Reinvested)
AWI leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AWI five years ago would be worth $16,301 today (with dividends reinvested), compared to $9,282 for STVN. Over the past 12 months, AWI leads with a +11.5% total return vs INGR's -18.4%. The 3-year compound annual growth rate (CAGR) favors AWI at 36.0% vs STVN's -13.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.4% | -1.3% | +3.6% | -16.0% | -0.7% |
| 1-Year ReturnPast 12 months | -17.0% | -2.8% | -2.2% | +11.5% | -18.4% |
| 3-Year ReturnCumulative with dividends | -35.9% | -0.1% | +26.6% | +151.8% | +7.9% |
| 5-Year ReturnCumulative with dividends | -7.2% | +12.9% | +24.2% | +63.0% | +28.8% |
| 10-Year ReturnCumulative with dividends | -7.2% | +10.5% | +160.5% | +330.4% | +13.5% |
| CAGR (3Y)Annualised 3-year return | -13.8% | -0.0% | +8.2% | +36.0% | +2.6% |
Risk & Volatility
Evenly matched — BCPC and INGR each lead in 1 of 2 comparable metrics.
Risk & Volatility
INGR is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than STVN's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BCPC currently trades 86.7% from its 52-week high vs STVN's 64.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.25x | 0.33x | 0.82x | 0.25x |
| 52-Week HighHighest price in past year | $28.00 | $49.99 | $183.90 | $206.08 | $141.78 |
| 52-Week LowLowest price in past year | $12.89 | $30.75 | $139.17 | $148.25 | $100.71 |
| % of 52W HighCurrent price vs 52-week peak | +64.4% | +73.2% | +86.7% | +80.1% | +75.8% |
| RSI (14)Momentum oscillator 0–100 | 82.1 | 53.6 | 32.9 | 41.3 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 583K | 253K | 190K | 494K | 585K |
Analyst Outlook
Evenly matched — APOG and INGR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: STVN as "Buy", APOG as "Hold", BCPC as "Buy", AWI as "Buy", INGR as "Hold". Consensus price targets imply 92.7% upside for APOG (target: $71) vs 1.6% for BCPC (target: $162). For income investors, INGR offers the higher dividend yield at 3.01% vs STVN's 0.34%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $24.50 | $70.50 | $162.00 | $197.50 | $124.25 |
| # AnalystsCovering analysts | 8 | 6 | 10 | 26 | 21 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +2.8% | +0.5% | +0.8% | +3.0% |
| Dividend StreakConsecutive years of raises | 0 | 14 | 11 | 8 | 3 |
| Dividend / ShareAnnual DPS | $0.05 | $1.04 | $0.87 | $1.27 | $3.24 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.9% | +2.1% | +1.8% | +3.3% |
AWI leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). APOG leads in 1 (Valuation Metrics). 2 tied.
STVN vs APOG vs BCPC vs AWI vs INGR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is STVN or APOG or BCPC or AWI or INGR a better buy right now?
For growth investors, Armstrong World Industries, Inc.
(AWI) is the stronger pick with 12. 1% revenue growth year-over-year, versus -2. 8% for Ingredion Incorporated (INGR). Ingredion Incorporated (INGR) offers the better valuation at 9. 6x trailing P/E (9. 6x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — STVN or APOG or BCPC or AWI or INGR?
On trailing P/E, Ingredion Incorporated (INGR) is the cheapest at 9.
6x versus Balchem Corporation at 33. 6x. On forward P/E, Ingredion Incorporated is actually cheaper at 9. 6x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Apogee Enterprises, Inc. wins at 0. 32x versus Stevanato Group S. p. A. 's 2. 48x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — STVN or APOG or BCPC or AWI or INGR?
Over the past 5 years, Armstrong World Industries, Inc.
(AWI) delivered a total return of +63. 0%, compared to -7. 2% for Stevanato Group S. p. A. (STVN). Over 10 years, the gap is even starker: AWI returned +330. 4% versus STVN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — STVN or APOG or BCPC or AWI or INGR?
By beta (market sensitivity over 5 years), Ingredion Incorporated (INGR) is the lower-risk stock at 0.
25β versus Stevanato Group S. p. A. 's 1. 45β — meaning STVN is approximately 478% more volatile than INGR relative to the S&P 500. On balance sheet safety, Balchem Corporation (BCPC) carries a lower debt/equity ratio of 15% versus 59% for Armstrong World Industries, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — STVN or APOG or BCPC or AWI or INGR?
By revenue growth (latest reported year), Armstrong World Industries, Inc.
(AWI) is pulling ahead at 12. 1% versus -2. 8% for Ingredion Incorporated (INGR). On earnings-per-share growth, the picture is similar: Balchem Corporation grew EPS 20. 9% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, AWI leads at 9. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — STVN or APOG or BCPC or AWI or INGR?
Armstrong World Industries, Inc.
(AWI) is the more profitable company, earning 19. 0% net margin versus 3. 9% for Apogee Enterprises, Inc. — meaning it keeps 19. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AWI leads at 26. 6% versus 6. 0% for APOG. At the gross margin level — before operating expenses — AWI leads at 40. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is STVN or APOG or BCPC or AWI or INGR more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Apogee Enterprises, Inc. (APOG) is the more undervalued stock at a PEG of 0. 32x versus Stevanato Group S. p. A. 's 2. 48x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Ingredion Incorporated (INGR) trades at 9. 6x forward P/E versus 30. 9x for Balchem Corporation — 21. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for APOG: 92. 7% to $70. 50.
08Which pays a better dividend — STVN or APOG or BCPC or AWI or INGR?
All stocks in this comparison pay dividends.
Ingredion Incorporated (INGR) offers the highest yield at 3. 0%, versus 0. 3% for Stevanato Group S. p. A. (STVN).
09Is STVN or APOG or BCPC or AWI or INGR better for a retirement portfolio?
For long-horizon retirement investors, Balchem Corporation (BCPC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 0. 5% yield, +160. 5% 10Y return). Both have compounded well over 10 years (BCPC: +160. 5%, STVN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between STVN and APOG and BCPC and AWI and INGR?
These companies operate in different sectors (STVN (Healthcare) and APOG (Industrials) and BCPC (Basic Materials) and AWI (Industrials) and INGR (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: STVN is a small-cap quality compounder stock; APOG is a small-cap deep-value stock; BCPC is a small-cap quality compounder stock; AWI is a small-cap quality compounder stock; INGR is a small-cap deep-value stock. APOG, BCPC, AWI, INGR pay a dividend while STVN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.